As the superficial fungal infection market becomes increasingly genericized, with two key patent expiries in 2004, market leaders need to adopt effective life-cycle management strategies to maintain market share. This Market Brief provides insight into the likely future direction of the superficial fungals market, with analysis of the optimal strategies for companies facing key patent losses.
Scope:
- Overview of superficial fungal infection patient potential, identifying key etiologic agents and reviewing disease epidemiology
- Assessment of current treatments, focusing on unmet needs and product differentiation
- Insight into approaches adopted by key players in the market to facilitate maintenance of market share
Report Highlights:
The increasing level of awareness regarding superficial fungal infections along with the rising disease prevalence, have led to an increase in patient potential.
OTC switching is playing an increasingly important role in the protection of market position, and will continue to do so following the loss of Diflucan and Lamisil patents in 2004.
Reformulation of existing products can extend brand awareness while providing consumers with a more appropriate treatment solution for a specific fungal infection.
Reasons to Purchase:
- Understand the limitations of superficial fungal patient potential and devise strategies to drive product uptake
- Identify key opportunities for fungal product reformulation or line extensions
- Analyze key strategies used to maintain superficial antifungal market share post patent expiry
